Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Leukemia & Lymphoma
|
August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia
Hussein A Abbas, Patrick K Reville, Alexis Geppner, et al.
The Lancet. Haematology
|
July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Tapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
Frontiers in Oncology
|
February 26, 2026
A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion
Dhabya Majid, Zhe Wang, Amanda M Schalk, et al.
Frontiers in Oncology
|
May 11, 2026
Correction: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion
Dhabya Majid, Zhe Wang, Amanda M Schalk, et al.
Iscience
|
January 15, 2026
Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML
Enes Dasdemir, Ivo Veletic, Christopher P Ly, et al.
American Journal of Hematology
|
January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
Patrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Blood Cancer Discovery
|
July 9, 2025
An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance
Cuijuan Han, Zhiping Zhang, Edie I Crosse, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
NPJ Precision Oncology
|
May 20, 2025
Multimodal spatial proteomic profiling in acute myeloid leukemia
Christopher P Ly, Ivo Veletic, Christopher D Pacheco, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Leukemia & Lymphoma
|
August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia
Hussein A Abbas, Patrick K Reville, Alexis Geppner, et al.
The Lancet. Haematology
|
July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Tapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
Frontiers in Oncology
|
February 26, 2026
A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion
Dhabya Majid, Zhe Wang, Amanda M Schalk, et al.
Frontiers in Oncology
|
May 11, 2026
Correction: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion
Dhabya Majid, Zhe Wang, Amanda M Schalk, et al.
Iscience
|
January 15, 2026
Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML
Enes Dasdemir, Ivo Veletic, Christopher P Ly, et al.
American Journal of Hematology
|
January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
Patrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Blood Cancer Discovery
|
July 9, 2025
An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance
Cuijuan Han, Zhiping Zhang, Edie I Crosse, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
NPJ Precision Oncology
|
May 20, 2025
Multimodal spatial proteomic profiling in acute myeloid leukemia
Christopher P Ly, Ivo Veletic, Christopher D Pacheco, et al.
Page
of 4